The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.
Metabolic Dysfunction–Associated Steatotic Liver Disease
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Glucagon-like peptide-1 receptor agonist (GLP1RA) alone [129] or GLP1RA-based combination agents, including dual (e.g., tirzepatide and survodutide) and triple (e.g., retatrutide) agonists, now demonstrate histological improvements in MASH and fibrosis with weight loss approaching that of bariatric surgery [3,130-133].”
In the citing paper
“The pan-PPAR agonist lanifibranor demonstrated significant MASH resolution and fibrosis improvement in clinical trials, though it was associated with weight gain [3,136].”
In the citing paper
“Importantly, resmetirom, a selective thyroid hormone receptor-β agonist, became the first U.S. Food and Drug Administration-approved drug for non-cirrhotic MASH with F2–F3 fibrosis.”
In the citing paper
“It has shown histologic improvement in MASH and liver fibrosis, as well as improvement of non-invasive biomarkers, with an acceptable safety profile [3,4].”
Citations
Cites
Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472
Self-citationA multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.06.003 · Cited by 3,100
Self-citationByrne, C. D., & Targher, G. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.12.012 · Cited by 3,042
Self-citationLudwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667
Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210
Self-citationA phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis
Harrison, S. A., Bedossa, P., Guy, C. D., Schattenberg, J. M., Loomba, R., Taub, R., Labriola, D., Moussa, S. E., Neff, G. W., Rinella, M. E., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309000 · Cited by 2,084
A Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039
Mechanisms and disease consequences of nonalcoholic fatty liver disease
Loomba, R., Friedman, S. L., & Shulman, G. I. (2021) · Cell · doi:10.1016/j.cell.2021.04.015 · Cited by 2,002
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
Sanyal, A. J., Newsome, P. N., Kliers, I., Østergaard, L. H., Long, M. T., Kjær, M. S., Cali, A. M. G., Bugianesi, E., Rinella, M. E., Roden, M., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2413258 · Cited by 1,115
Research works printed but not linked: 1
- 10.1136/gutjnl-2020-323082 · DOI · Paper page
Cited by
Truong, X. T., & Lee, D. H. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0644 · Cited by 84
Caturano, A., Erul, E., Nilo, R., Nilo, D., Russo, V., Rinaldi, L., Acierno, C., Akkuş, E., Koudelková, K., Cerini, F., et al. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70132 · Cited by 40
Petta, S., Kim, K., Targher, G., Romeo, S., Sookoian, S. C., Zheng, M., Aghemo, A., & Valenti, L. V. C. (2025) · Liver International · doi:10.1111/liv.70407 · Cited by 34
Self-citationHuman genetics of steatotic liver disease: insights into insulin resistance and lipid metabolism
Mancina, R. M., Valenti, L. V. C., & Romeo, S. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01394-8 · Cited by 31
Self-citationZhou, X., Fan, Q.-Y., Targher, G., Byrne, C. D., Chen, Q., Shapiro, M. D., Dong, Y.-X., Sung, K., Lip, G. Y. H., Lazarus, J. V., et al. (2026) · Science China Life Sciences · doi:10.1007/s11427-025-3193-9 · Cited by 27
Self-citation
Metadata
- Authors
- Targher, G., Valenti, L., & Byrne, C. D.
- Affiliations
- University of Verona (IT)
- University of Milan (IT)
- University Hospital Southampton NHS Foundation Trust (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-08-14
- Volume
- 393
- Issue
- 7
- Pages
- 683-698
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4413117974
- Cited by
- 325
- References
- 82
- Citations by year
- 2026: 285 · 2025: 40
- FWCI
- 49.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, hepatic steatosis, metabolic dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metabolic Dysfunction–Associated Steatotic Liver Disease. https://app.cochat.ai/papers/10.1056/nejmra2412865
- The paper
- Targher, G., Valenti, L., & Byrne, C. D. (2025). Metabolic Dysfunction–Associated Steatotic Liver Disease. New England Journal of Medicine. https://doi.org/10.1056/nejmra2412865
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.